Metric Finance
LearnFAQ
LearnFAQ

Learn / STLN

NASDAQ: STLN

Starling Oncology (STLN) stock, explained like you're 5

Starling Oncology trades on the Nasdaq under the ticker STLN. It is a small cap company in the medical/nursing services industry, part of the healthcare sector, with a market value of about 676 million dollars.

Ticker
STLN
Exchange
Nasdaq
Sector
Healthcare
Industry
Medical/Nursing Services
Size
Small cap, about 676 million dollars

Is Starling Oncology a small, medium or large cap company?

No. Starling Oncology is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 676 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Starling Oncology makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves STLN stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views (Yahoo Finance)
  • Starling Oncology (STLN) Stock Forum and Discussion (Moomoo)
  • Needham raises Starling Oncology stock price target on growth outlook (Investing.com)
  • symbol__ Stock Quote Price and Forecast (CNN)
  • The Oncology Institute, Inc. (STLN) stock price, news, quote and history (Yahoo Finance UK)

Follow STLN in your daily brief

Each trading day at 5 PM ET we post what happened to Starling Oncology and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow STLN

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Starling Oncology stock

What does Starling Oncology do?

Starling Oncology trades on the Nasdaq under the ticker STLN. It is a small cap company in the medical/nursing services industry, part of the healthcare sector, with a market value of about 676 million dollars.

What is the ticker symbol for Starling Oncology?

Starling Oncology trades under the ticker STLN on the Nasdaq.

What is Starling Oncology's market cap?

Starling Oncology is a small cap stock with a market cap of about 676 million dollars.

How does Starling Oncology make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves STLN stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow STLN stock every day?

Add STLN to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow STLN daily

A free brief on Starling Oncology and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • BTSGU · BrightSpring Health Services
  • BTSG · BrightSpring Health Services
  • HIMS · Hims & Hers Health
  • CHE · Chemed

Similar stocks

  • BTSGUBrightSpring Health Services
  • BTSGBrightSpring Health Services
  • HIMSHims & Hers Health
  • CHEChemed

Compare STLN: STLN vs BTSGU, STLN vs BTSG, STLN vs HIMS

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed